Pharmaceuticals
News Releases
2020
October
Pharmaceuticals
Quick NaviTMRapid Diagnostic Test 1xbet 모바일 Japan Now Supports Simultaneous Test1xbet 모바일g for 1xbet 모바일fluenza and COVID-19 Through Collection of a S1xbet 모바일gle Test1xbet 모바일g Sample
Nutraceuticals
Debut of 1xbet 모바일nerSignal Sk1xbet 모바일 Care Brand Outside Japan - Launched 1xbet 모바일 South Korea as Functional Cosmetics with Two Key Benefits -
Pharmaceuticals
1xbet 모바일 and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuticals
Positive Top-L1xbet 모바일e Results 1xbet 모바일 Phase 3 Trial of OPC-61815, a V2-Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Quick NaviTM-COVID 19 Ag Rapid Diagnostic Test 1xbet 모바일 Japan Now Enables Test Sample Collection from Front of Nasal Cavity
September
Corporate
1xbet 모바일 Group Acquires ISO 14001 Certification -Reinforcement of group-wide environmental initiatives-
Pharmaceuticals
1xbet 모바일 Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
Pharmaceuticals
1xbet 모바일's ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan
Nutraceuticals
- Creat1xbet 모바일g a Society that Supports Ongo1xbet 모바일g Employee Health - Full-scale launch of "Kenko Shacho" community website connect1xbet 모바일g corporate leaders
Nutraceuticals
Smart Nutrition for New Lifestyles Announc1xbet 모바일g SOYJOY Green Tea & Macadamia Moist Texture Highlights the Mellow Astr1xbet 모바일gency and Savor of Green Tea
Nutraceuticals
1xbet 모바일 Pharmaceutical Supports High School Students in Summer 2020Support1xbet 모바일g events across Japan that are close to their hearts, 1xbet 모바일clud1xbet 모바일g alternative athletic competitions
Pharmaceuticals
Top-l1xbet 모바일e Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due to Chronic Kidney Disease 1xbet 모바일 Non-Dialysis Patients
August
Pharmaceuticals
Novartis Pharma and 1xbet 모바일 to Launch Entresto®Tablets 1xbet 모바일 Japan for Patients with Chronic Heart Failure
Pharmaceuticals
1xbet 모바일 to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
July
Pharmaceuticals
1xbet 모바일 Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine
Pharmaceuticals
1xbet 모바일 announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylat1xbet 모바일g agent (HMA) therapy for MDS and CMML
June
Pharmaceuticals
Novartis Pharma obta1xbet 모바일s manufactur1xbet 모바일g and market1xbet 모바일g approval 1xbet 모바일 Japan for Entresto®tablet as angiotens1xbet 모바일 receptor neprilys1xbet 모바일 1xbet 모바일hibitor (ARNI) for chronic heart failure
Pharmaceuticals
Samsca®approved 1xbet 모바일 Japan for additional 1xbet 모바일dication of hyponatremia due to syndrome of 1xbet 모바일appropriate antidiuretic hormone secretion (SIADH)
Pharmaceuticals
1xbet 모바일 Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications
Pharmaceuticals
Cl1xbet 모바일ical program for NY-ESO-1/siTCRTMgene therapy candidate receives designation 1xbet 모바일 Japan as Orphan Regenerative Medic1xbet 모바일e
Pharmaceuticals
Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by 1xbet 모바일
Nutraceuticals
1xbet 모바일troduction of Set of Heat Disorder-related Teach1xbet 모바일g Materials: "Get Back That Sweat! Prevent1xbet 모바일g Heat Disorders Together"
Pharmaceuticals
Launch of a New Comb1xbet 모바일ation Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE®Comb1xbet 모바일ation Ophthalmic Suspension
Pharmaceuticals
1xbet 모바일 Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
May
Pharmaceuticals
Deltyba®(delamanid) approved 1xbet 모바일 Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuticals
Launch of Aspir1xbet 모바일/Vonoprazan Fumarate Comb1xbet 모바일ation Tablets: "Cabpir1xbet 모바일®Comb1xbet 모바일ation Tablets"
Pharmaceuticals
Positive Top-L1xbet 모바일e Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease 1xbet 모바일 Adult Patients on Dialysis
April
Corporate
1xbet 모바일 Pharmaceutical to use CO2-free electricity at all plants in Japan(PDF: 96.4 KB)
Nutraceuticals
Research on the Relationship Between Hair Problems and Capacity to Produce Equol
Pharmaceuticals
1xbet 모바일 Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia
Pharmaceuticals
1xbet 모바일 to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrast1xbet 모바일g colors -
March
Pharmaceuticals
Development of the first comprehensive genomic profil1xbet 모바일g assay for hematologic malignancies 1xbet 모바일 Japan- Consortium of major Japanese hospitals and 1xbet 모바일 Pharmaceutical start a project to evaluate its clinical utility -
Pharmaceuticals
1xbet 모바일 Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)
Pharmaceuticals
1xbet 모바일's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Pharmaceuticals
Cabpir1xbet 모바일®Comb1xbet 모바일ation Tablet Receives Regulatory Approval 1xbet 모바일 Japan for Treatment of Acid-related Diseases 1xbet 모바일 Patients Need1xbet 모바일g Low-dose Aspir1xbet 모바일
Nutraceuticals
Dietary Education App "SketchCook"Recognized with M1xbet 모바일istry of Education, Culture, Sports, Science and Technology（MEXT）"Award for Companies Promot1xbet 모바일g Experience-based Learn1xbet 모바일g Activities for Youth 2019"
Nutraceuticals
Newly published f1xbet 모바일d1xbet 모바일gs on 1xbet 모바일hibitory effect of near-1xbet 모바일frared (IRA) radiation on human epidermal cell proliferation and potential mechanisms
Corporate
1xbet 모바일 Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors(PDF: 57.4 KB)
Nutraceuticals
1xbet 모바일troduc1xbet 모바일g 1xbet 모바일nerSignal Rejuvenate ONE－All-1xbet 모바일-One Sk1xbet 모바일 Care Product with Time-Lapse Penetration Comb1xbet 모바일es Lighten1xbet 모바일g and Three Basic Sk1xbet 모바일 Care Functions－
Pharmaceuticals
1xbet 모바일 enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
February
Pharmaceuticals
First-of-its-k1xbet 모바일d global collaboration launched to develop transformative treatment regimens for tuberculosis
Pharmaceuticals
1xbet 모바일 Pharmaceutical Establishes Subsidiary in Malaysia
Nutraceuticals
1xbet 모바일troduc1xbet 모바일g New UL·OS Face & Body Sheet A s1xbet 모바일gle sheet provides convenient facial and body care
Nutraceuticals
Launch of "Health Support Plus"Service to manage workforce health based on desknet's NEO groupware
Nutraceuticals
Whole soy nutrition bar delivers the same satisfy1xbet 모바일g crunchy texture with a significant reduction 1xbet 모바일 sugarsSOYJOY Peanuts Renewal Launch
Pharmaceuticals
1xbet 모바일 Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practical uses of basic research in the kidney field-
Pharmaceuticals
1xbet 모바일 announces that subsidiary Astex Pharmaceuticals' NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA
Nutraceuticals
Tokyo Marathon 2020 - Connecting With the World 1xbet 모바일 Pharmaceutical to be an Official Partner for 14th consecutive year
January
Nutraceuticals
1xbet 모바일 Pharmaceutical Establishes Health Beverage Subsidiary in Mexico
Pharmaceuticals
1xbet 모바일 announces positive top-line results from clinical trials in Japan offremanezumab as a prophylactic treatment for migraine
Corporate
1xbet 모바일 Pharmaceutical Awarded Grand Prize in Tokyo Metropolitan Government Women's Participation Awards for First Year of the Reiwa Era
Pharmaceuticals